Black Diamond Therapeutics Inc (BDTX) Stock Price, Quote & News

Company Profile

Black Diamond Therapeutics, Inc., a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in Phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as Phase 1 clinical trial to treat glioblastoma. It is also develo...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 252 0848

Website: www.blackdiamondtherapeutics.com

Address:

One Main Street, 14th Floor, Cambridge, United States

Bbboston Dec. 5 at 5:08 PM

$BDTX Somebody picked up a chuck of shares early in the session. That what I think triggered that early jump.

0 · Reply

Benalish Dec. 5 at 2:50 PM

$BDTX She's getting ready to move!

1 · Reply

100K2022 Dec. 5 at 2:47 PM

$BDTX added yesterday, 10K at 3.43.

0 · Reply

PLATINUM_TRADES Dec. 5 at 2:26 PM

$BDTX Overnight swing.. Looks $3.00 may break nice pop so far 🚨 🚨

0 · Reply

signaljumper Dec. 5 at 10:48 AM

$BDTX do drop was to much. Loaded Yesterday

0 · Reply

Benalish Dec. 4 at 8:06 PM

$BDTX I see what happened. They got effectiveness on 12/3/25 so they can sell shares if they want to. But it doesn't mean they did, but investors took it to mean they were going to sell. That's why it dropped instead of going up on the news. Just really bad timing that they release news the same date as the S-3 effectiveness:

2 · Reply

_www_larval_com_ Dec. 4 at 7:27 PM

Look $BDTX has reverted 3% higher to -1% (~2Mv) a few minutes ago, 12/19 options, follow for more volatility.

0 · Reply

soulsearche Dec. 4 at 7:25 PM

$BDTX 5)They were very positive on the results and the unique mechanism of their drug - can attack CNS metastasis which is common in lung cancer, - works for sever EGFR mutations that the SOC (astra zeneca drug) does not work on. My take take they my soon have a deal and or partnership announcement also dont forget a potential milestone payment from Servier. Announcement of partnership bef

0 · Reply

soulsearche Dec. 4 at 7:25 PM

$BDTX For those who did not listen to today's call. 1) Adverse events are higher in front line patients as they are not acclimatized to treatment and drugs. Recurrent patients show lesser adverse events. 2) theya are likely to receive milestone payment from servier in the near future, which has not even been counted in the cash run they have 3) they had started partnership talk since August as these things take time. Are looking for a right partnership structure taht can do justice to the drug and shareholders 4) they are open to partnering on NSCLC alone and runt he GBM smaller trial of 150 patients themselves we the partner is not willing to giving the vale for GBM contd.....

0 · Reply

Benalish Dec. 4 at 5:10 PM

$BDTX These fake pull backs from positive data don't last long. Enjoy the low prices while they last.

1 · Reply

Black Diamond's Lung Cancer Drug Shows 60% Response Rate In Phase 2 Data

Dec 3, 2025, 7:01 AM EST - 2 days ago

Black Diamond Therapeutics Announces Preliminary Phase 2 Data for Silevertinib in 1L NSCLC and Plans for a Phase 2 Trial of Silevertinib in GBM

Dec 2, 2025, 4:01 PM EST - 3 days ago

Black Diamond Therapeutics to Host Webcast Presentation Highlighting Silevertinib Phase 2 Clinical Trial Results and Program Update

Nov 20, 2025, 8:57 AM EST - 15 days ago

Black Diamond Therapeutics: Underappreciated Despite An Upcoming Key Readout

Nov 6, 2025, 4:01 PM EST - 4 weeks ago

Black Diamond Therapeutics to Participate in Upcoming Investor Conferences

Nov 6, 2025, 7:30 AM EST - 4 weeks ago

Black Diamond Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Oct 10, 2025, 4:32 AM EDT - 2 months ago

4 Biotechnology Stocks Lead Momentum Gains Amid Strong Technicals

ALDX ALEC CHRS

Aug 25, 2025, 11:13 AM EDT - 3 months ago

Black Diamond Therapeutics: A Potential First-Line In NSCLC Trading At Cash

Aug 7, 2025, 8:23 AM EDT - 4 months ago

Black Diamond (BDTX) Q2 Loss Narrows 47%

Aug 7, 2025, 7:30 AM EDT - 4 months ago

Black Diamond Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Jun 10, 2025, 6:38 AM EDT - 6 months ago

Black Diamond Therapeutics: Targeted Approach And Early Efficacy Signals Create Potential For Significant Upside

May 29, 2025, 8:00 AM EDT - 6 months ago

Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference

May 12, 2025, 4:05 PM EDT - 7 months ago

Black Diamond Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

Mar 25, 2025, 12:58 AM EDT - 9 months ago

Black Diamond Therapeutics Trades Well Below Cash After Lucrative Deal With Servier

Mar 19, 2025, 7:00 AM EDT - 9 months ago

Servier and Black Diamond Therapeutics Announce Global Licensing Agreement for BDTX-4933, A Targeted Oncology Therapy

Mar 13, 2025, 3:47 PM EDT - 9 months ago

Black Diamond Therapeutics: In Decline, But Why?

Mar 6, 2025, 4:01 PM EST - 9 months ago

Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Dec 30, 2024, 3:07 PM EST - 1 year ago

Black Diamond Therapeutics: Speculative Buy With Precision Oncology Catalysts

Nov 5, 2024, 8:00 AM EST - 1 year ago

Black Diamond Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Oct 8, 2024, 3:24 PM EDT - 1 year ago

Black Diamond: EGFRm NSCLC Targeting Continues With Q1 Of 2025 Data

Oct 7, 2024, 4:01 PM EDT - 1 year ago

Black Diamond Therapeutics Announces Restructuring Plan to Focus Resources on BDTX-1535 and Extend Cash Runway

Sep 23, 2024, 7:00 AM EDT - 1 year ago

Black Diamond Therapeutics Announces Initial Phase 2 Data Demonstrating Robust Anti-tumor Activity of BDTX-1535 in Patients with Recurrent EGFRm NSCLC who Present with a Broad Spectrum of Classical, Non-classical, and C797S Resistance Mutations

Sep 22, 2024, 10:00 AM EDT - 1 year ago

Black Diamond Therapeutics to Host Webcast Presentation of Initial Phase 2 BDTX-1535 Data in Patients With Recurrent EGFRm NSCLC

Sep 14, 2024, 3:30 AM EDT - 1 year ago

Black Diamond Therapeutics Presents Real-World Treatment Practices and Patient Outcomes in Newly Diagnosed NSCLC Patients with Non-Classical Mutations at the European Society for Medical Oncology (ESMO) Congress 2024

Aug 6, 2024, 7:30 AM EDT - 1 year ago

Black Diamond Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Jun 27, 2024, 10:38 AM EDT - 1 year ago

Black Diamond: High-Risk, High-Reward, Low-Profile EGFR Inhibitor Worth A Deep Dive

Jun 1, 2024, 10:00 AM EDT - 1 year ago

Black Diamond Therapeutics Presents Promising BDTX-1535 Clinical Data in Patients with Recurrent Glioblastoma at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

May 9, 2024, 7:30 AM EDT - 1 year ago

Black Diamond Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

Apr 24, 2024, 4:05 PM EDT - 1 year ago

Black Diamond Therapeutics Announces Presentations at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 11, 2024, 8:00 AM EDT - 1 year ago

Black Diamond Therapeutics Announces Changes to Board of Directors

Apr 7, 2024, 6:00 PM EDT - 1 year ago

Black Diamond Therapeutics Presents Novel Real-World Evidence of the Evolving EGFR Mutation Landscape in NSCLC and the Opportunity for BDTX-1535 in an Oral Presentation at the 2024 American Association of Cancer Research Annual Meeting

Mar 24, 2024, 11:25 PM EDT - 1 year ago

Rise Of The Rest, Look Past Mega Caps, And Invest Elsewhere

AAPL AER AMZN BA DFH DHI GE

Mar 12, 2024, 8:00 AM EDT - 1 year ago

Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Mar 5, 2024, 4:30 PM EST - 1 year ago

Black Diamond Therapeutics Announces Upcoming Presentation at AACR Annual Meeting 2024

Feb 28, 2024, 8:00 AM EST - 1 year ago

Black Diamond Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference

Jan 12, 2024, 5:21 PM EST - 2 years ago

Black Diamond Therapeutics: Emerging Data In EGFR-Mutant NSCLC And GBM

Jan 4, 2024, 8:00 AM EST - 2 years ago

Black Diamond Therapeutics Announces Corporate Update and Expected 2024 Milestones

Dec 13, 2023, 7:00 AM EST - 2 years ago

Black Diamond Therapeutics Announces Topline Results from Phase 1 Dose Escalation Trial of BDTX-1535 in Patients with Recurrent GBM

Nov 6, 2023, 7:45 AM EST - 2 years ago

Black Diamond Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Oct 14, 2023, 12:30 PM EDT - 2 years ago

Black Diamond Therapeutics Presents Dose Escalation Data Demonstrating Durable Responses in Patients with NSCLC from Phase 1 Trial of BDTX-1535

Oct 12, 2023, 8:31 AM EDT - 2 years ago

Black Diamond's BDTX-1535: A Brainy Bet In Cancer Therapy

Oct 4, 2023, 12:14 PM EDT - 2 years ago

Black Diamond Therapeutics to Present Preclinical and Clinical Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Sep 18, 2023, 7:00 AM EDT - 2 years ago

Black Diamond Therapeutics Announces CEO Transition

Sep 11, 2023, 8:00 AM EDT - 2 years ago

Black Diamond Therapeutics Announces First Patients Dosed in Phase 1 Clinical Trial Expansion Cohorts Evaluating BDTX-1535 in Patients with Intrinsic Driver and Acquired Resistance EGFR Mutation Positive Non-Small Cell Lung Cancer

Aug 11, 2023, 7:30 AM EDT - 2 years ago

Black Diamond Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Aug 3, 2023, 8:53 AM EDT - 2 years ago

Black Diamond Therapeutics: MasterKey Approach Validated With Lung Cancer Update

Jun 29, 2023, 8:57 PM EDT - 2 years ago

Black Diamond Therapeutics Announces Pricing of Public Offering of Common Stock

Jun 29, 2023, 5:48 PM EDT - 2 years ago

Why Shares of Black Diamond Therapeutics Skyrocketed This Week

Jun 28, 2023, 6:51 PM EDT - 2 years ago

Black Diamond: On Right Track For Possible Accelerated Approval Pathway

Jun 28, 2023, 4:23 PM EDT - 2 years ago

Black Diamond Therapeutics Announces Proposed Public Offering of Common Stock

Bbboston Dec. 5 at 5:08 PM

$BDTX Somebody picked up a chuck of shares early in the session. That what I think triggered that early jump.

0 · Reply

Benalish Dec. 5 at 2:50 PM

$BDTX She's getting ready to move!

1 · Reply

100K2022 Dec. 5 at 2:47 PM

$BDTX added yesterday, 10K at 3.43.

0 · Reply

PLATINUM_TRADES Dec. 5 at 2:26 PM

$BDTX Overnight swing.. Looks $3.00 may break nice pop so far 🚨 🚨

0 · Reply

signaljumper Dec. 5 at 10:48 AM

$BDTX do drop was to much. Loaded Yesterday

0 · Reply

Benalish Dec. 4 at 8:06 PM

2 · Reply

_www_larval_com_ Dec. 4 at 7:27 PM

Look $BDTX has reverted 3% higher to -1% (~2Mv) a few minutes ago, 12/19 options, follow for more volatility.

0 · Reply

soulsearche Dec. 4 at 7:25 PM

0 · Reply

soulsearche Dec. 4 at 7:25 PM

0 · Reply

Benalish Dec. 4 at 5:10 PM

$BDTX These fake pull backs from positive data don't last long. Enjoy the low prices while they last.

1 · Reply

garbageshort Dec. 4 at 4:02 PM

$BDTX Journey below 2$ has started ...

1 · Reply

Bromberger Dec. 4 at 3:37 PM

$BDTX Biotech Growth N.V. dumped again right after good data — same pattern as in April. Hopefully they’re finally out. The dump was totally illogical. Now it’s time for a move back to normal levels. 5–6$ back in play.

0 · Reply

xale30x Dec. 4 at 2:47 PM

$BDTX

0 · Reply

JarvisFlow Dec. 4 at 1:47 PM

Guggenheim has adjusted their stance on Black Diamond Therapeutic ( $BDTX ), setting the rating to Neutral.

1 · Reply

VictorVVV Dec. 4 at 12:25 PM

$BDTX Gemini regarding $BDTX give me a short summary again of what we spoke about yesterday. Why this stock, whether yesterday's news was good or bad and why is it a good company and why is it oversold? And mention those big boy buys all across regular session yesterday? Also how much cash company has and for how long? Also what's the number the analyst give it which you said it's $9 per share.

1 · Reply

Windy007 Dec. 4 at 12:14 PM

$BDTX

1 · Reply

Windy007 Dec. 4 at 12:10 PM

$BDTX

0 · Reply

Marklacey123 Dec. 4 at 6:09 AM

$BDTX OVERNIGHT BROKER UPDATES JEFFERIES BUY PT $9 STIFEL BUY PT 8 HC WAINWRIGHT BUY 10 PIPER SANDLER OVERWEIGHT 9 WEDBUSH OUTPERFORM 13 RAYMOND JAMES OUTPERFORM 11

0 · Reply

justiceforb_85 Dec. 4 at 2:09 AM

$BDTX over-reaction as I think silevertinib will have a place in 1L non-classical mutations with the exception of PACC where $AVBP will be the leader. Main concern is whether BP will partner with (or buy outright) the company to run a P3 for non-classical NSCLC.

1 · Reply

soulsearche Dec. 4 at 12:03 AM

$BDTX Very funny, the stock was not rewarded for great data but punished on management decision to pursue GBM or punished because some analyst decided tor some reasons to help the shorts cover and so revised the rating to neutral. If the data was really good and institutional money in watching, this cannot stay down here will rather be upward of $4 soon imo

1 · Reply

REKEV1 Dec. 3 at 10:52 PM

$BDTX 3,5 USD+ eow

1 · Reply

OpenOutcrier Dec. 3 at 9:01 PM

RECAP 12/3 -Neg Comments: $CHTR - CFRA $AEG - UBS $DEO - UBS $BDTX - Guggenheim $GTLB - Macquarie Live Breaking trading news www.openoutcrier.com

0 · Reply

Market Cap	154.40M
Revenue (ttm)	0.00
Net Income (ttm)	-69.68M
EPS (ttm)	N/A
PE Ratio	7.47
Forward PE	5.64
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	2,108,800
Avg Vol	1,271,946
Day's Range	N/A - N/A
Shares Out	56.98M
Stochastic %K	25%
Beta	3.33
Analysts	Strong Sell
Price Target	$10.00